$ACUR
ACURA PHARMACEUTICALS, INC

2016 Q4 Form 10-K Financial Statement

#000114420417018146 Filed on March 31, 2017

View on sec.gov

Income Statement

Concept 2016 Q4 2016 2015 Q4
Revenue $3.765M $4.464M $2.679M
YoY Change 40.54% -48.01% 406.43%
Cost Of Revenue $140.0K $451.0K $100.0K
YoY Change 40.0% -31.25% 150.0%
Gross Profit $3.620M $4.013M $2.580M
YoY Change 40.31% -49.4% 426.53%
Gross Profit Margin 96.15% 89.9% 96.3%
Selling, General & Admin $1.120M $6.516M $2.590M
YoY Change -56.76% -27.55% 26.96%
% of Gross Profit 30.94% 162.37% 100.39%
Research & Development $770.0K $4.028M $700.0K
YoY Change 10.0% 54.45% -23.08%
% of Gross Profit 21.27% 100.37% 27.13%
Depreciation & Amortization $90.00K $100.0K $90.00K
YoY Change 0.0% 0.0% -52.63%
% of Gross Profit 2.49% 2.49% 3.49%
Operating Expenses $1.900M $10.54M $3.290M
YoY Change -42.25% -9.12% 10.25%
Operating Profit $1.729M -$6.557M -$710.0K
YoY Change -343.52% 63.88% -71.08%
Interest Expense -$200.0K $893.0K -$210.0K
YoY Change -4.76% -22.82% -12.5%
% of Operating Profit -11.57%
Other Income/Expense, Net $0.00 -$831.0K $0.00
YoY Change -15.89%
Pretax Income $1.530M -$7.388M -$920.0K
YoY Change -266.3% 48.09% -65.93%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $1.534M -$7.388M -$916.0K
YoY Change -267.47% 48.09% -66.02%
Net Earnings / Revenue 40.74% -165.5% -34.19%
Basic Earnings Per Share $0.13 -$0.62 -$0.08
Diluted Earnings Per Share $0.13 -$0.62 -$0.08
COMMON SHARES
Basic Shares Outstanding 11.87M shares 11.80M shares
Diluted Shares Outstanding 11.87M shares

Balance Sheet

Concept 2016 Q4 2016 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.681M $2.681M $13.32M
YoY Change -79.88% -75.26% 10.14%
Cash & Equivalents $2.681M $2.681M $2.485M
Short-Term Investments $0.00 $0.00 $10.84M
Other Short-Term Assets $2.770M $2.768M $2.910M
YoY Change -4.81% -4.62% 321.74%
Inventory $309.0K $309.0K $276.0K
Prepaid Expenses
Receivables $100.0K $102.0K $83.00K
Other Receivables $50.00K $50.00K $40.00K
Total Short-Term Assets $5.910M $5.910M $14.14M
YoY Change -58.19% -58.19% 6.83%
LONG-TERM ASSETS
Property, Plant & Equipment $867.0K $867.0K $1.013M
YoY Change -14.41% -14.41% 5.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $180.0K
YoY Change -100.0% -100.0%
Total Long-Term Assets $2.298M $2.298M $2.826M
YoY Change -18.68% -18.68% 0.86%
TOTAL ASSETS
Total Short-Term Assets $5.910M $5.910M $14.14M
Total Long-Term Assets $2.298M $2.298M $2.826M
Total Assets $8.208M $8.208M $16.96M
YoY Change -51.61% -51.61% 5.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $77.00K $77.00K $110.0K
YoY Change -30.0% -30.0% -49.31%
Accrued Expenses $703.0K $703.0K $564.0K
YoY Change 24.65% 24.65% -0.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.376M $2.376M $2.320M
YoY Change 2.41% 2.41% 31.97%
Total Short-Term Liabilities $3.487M $3.487M $3.244M
YoY Change 7.49% 7.49% 8.42%
LONG-TERM LIABILITIES
Long-Term Debt $2.979M $2.979M $5.430M
YoY Change -45.14% -45.14% -30.38%
Other Long-Term Liabilities $560.0K $559.0K $390.0K
YoY Change 43.59% 44.44% 105.26%
Total Long-Term Liabilities $2.979M $3.538M $5.430M
YoY Change -45.14% -39.18% -30.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.487M $3.487M $3.244M
Total Long-Term Liabilities $2.979M $3.538M $5.430M
Total Liabilities $7.025M $7.025M $9.061M
YoY Change -22.47% -22.47% -17.48%
SHAREHOLDERS EQUITY
Retained Earnings -$374.7M -$367.3M
YoY Change 2.01% 1.38%
Common Stock $375.9M $375.3M
YoY Change 0.16% 2.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.183M $1.183M $7.900M
YoY Change
Total Liabilities & Shareholders Equity $8.208M $8.208M $16.96M
YoY Change -51.61% -51.61% 5.79%

Cashflow Statement

Concept 2016 Q4 2016 2015 Q4
OPERATING ACTIVITIES
Net Income $1.534M -$7.388M -$916.0K
YoY Change -267.47% 48.09% -66.02%
Depreciation, Depletion And Amortization $90.00K $100.0K $90.00K
YoY Change 0.0% 0.0% -52.63%
Cash From Operating Activities $1.780M -$5.563M -$1.060M
YoY Change -267.92% 50.84% -54.89%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $75.00K $0.00
YoY Change -64.95% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.87M $1.020M
YoY Change -100.0% 3276.71% -46.6%
Cash From Investing Activities $0.00 $10.80M $1.020M
YoY Change -100.0% 9898.15% -45.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -870.0K -$2.539M -800.0K
YoY Change 8.75% -147.99%
NET CHANGE
Cash From Operating Activities 1.780M -$5.563M -1.060M
Cash From Investing Activities 0.000 $10.80M 1.020M
Cash From Financing Activities -870.0K -$2.539M -800.0K
Net Change In Cash 910.0K $2.696M -840.0K
YoY Change -208.33% 57.57% 78.72%
FREE CASH FLOW
Cash From Operating Activities $1.780M -$5.563M -$1.060M
Capital Expenditures -$10.00K $75.00K $0.00
Free Cash Flow $1.790M -$5.638M -$1.060M
YoY Change -268.87% 44.49% -54.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
1534000 USD
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
368000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51036000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
56622000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51036000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56622000 USD
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2016 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
2100000 USD
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2016 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
47200000 USD
CY2016Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
138800000 USD
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1320000 USD
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1394000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
57000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
38000 USD
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
332000 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
47192000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
52772000 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
2135000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
2050000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
335000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.85
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.92
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.89
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.18
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6000 USD
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
400000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
199000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
248000 shares
CY2015 us-gaap Sale Leaseback Transaction Transaction Costs Financing Activities
SaleLeasebackTransactionTransactionCostsFinancingActivities
8000 USD
CY2015 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
217000 USD
acur Placement Agency Reimbursed For Expenses
PlacementAgencyReimbursedForExpenses
496000 USD
CY2013Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10000000 USD
CY2013Q4 acur Debt Default Long Term Debt Percentage
DebtDefaultLongTermDebtPercentage
0.1335 pure
CY2016 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
260000 USD
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5600000 USD
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
600000 USD
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2512000 USD
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1696000 USD
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
41000 USD
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0 USD
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
49000 USD
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
159000 USD
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
184000 USD
CY2016 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
2000 USD
CY2015 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
11000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2302000 USD
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1460000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
384000 shares
CY2016 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2018-12-01
CY2015Q1 acur Debt Instrument Cash Maintenance
DebtInstrumentCashMaintenance
2500000 USD
CY2016Q4 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
50000 USD
CY2016 acur Debt Consulting Placement Fee
DebtConsultingPlacementFee
100000 USD
CY2016Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.1016 pure
CY2016 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
2540000 USD
CY2016 acur Debt Instrument Classification Amount
DebtInstrumentClassificationAmount
0 USD
CY2015Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8040000 USD
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5500000 USD
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
95000 USD
CY2015Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
193000 USD
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
98000 USD
CY2015Q4 acur Debt Instrument Issuance Costs
DebtInstrumentIssuanceCosts
-97000 USD
CY2016 acur Amortization Expense Of Debt Instrument Issuance Costs
AmortizationExpenseOfDebtInstrumentIssuanceCosts
50000 USD
CY2016Q4 acur Debt Instrument Issuance Costs
DebtInstrumentIssuanceCosts
-47000 USD
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
5355000 USD
CY2016 us-gaap Depreciation
Depreciation
100000 USD
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
70000 USD
CY2014Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0 USD
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
32000 USD
CY2016 acur Inventory Reserve Expense Raw And Packagings
InventoryReserveExpenseRawAndPackagings
0 USD
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1457000 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1258000 shares
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
637000 USD
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
611000 USD
CY2016 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
200000 USD
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Entity Registrant Name
EntityRegistrantName
ACURA PHARMACEUTICALS, INC
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0000786947
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
95000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
64000 USD
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q2 dei Entity Public Float
EntityPublicFloat
13700000 USD
CY2016 dei Trading Symbol
TradingSymbol
ACUR
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11883339 shares
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7000 USD
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
91000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
569000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
362000 USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11834000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11801000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11834000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11801000 shares
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
82000 USD
CY2015 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2016 us-gaap Principal Transactions Revenue
PrincipalTransactionsRevenue
0 USD
CY2015 us-gaap Principal Transactions Revenue
PrincipalTransactionsRevenue
8000 USD
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
603000 USD
CY2015Q4 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
92000 USD
CY2016 acur Interest Expense Debt Discount
InterestExpenseDebtDiscount
95000 USD
CY2015 acur Interest Expense Debt Discount
InterestExpenseDebtDiscount
121000 USD
CY2016Q4 acur Marketing Advertising And Promotion
MarketingAdvertisingAndPromotion
10000 USD
CY2015Q4 acur Marketing Advertising And Promotion
MarketingAdvertisingAndPromotion
115000 USD
CY2016Q4 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
233000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1858000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1741000 USD
CY2016 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
50000 USD
CY2015 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
65000 USD
CY2016 us-gaap Interest Expense Debt
InterestExpenseDebt
748000 USD
CY2015 us-gaap Interest Expense Debt
InterestExpenseDebt
971000 USD
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2521000 USD
CY2016Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2979000 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
116000 USD
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
101000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
232000 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
171000 USD
CY2016Q4 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
1000 USD
CY2015Q4 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
6000 USD
CY2016Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
16000 USD
CY2015Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
15000 USD
CY2015 acur Inventory Reserve Expense Raw And Packagings
InventoryReserveExpenseRawAndPackagings
260000 USD
CY2016 acur Inventory Valuation Written Off Raw And Package
InventoryValuationWrittenOffRawAndPackage
0 USD
CY2015 acur Inventory Valuation Written Off Raw And Package
InventoryValuationWrittenOffRawAndPackage
-260000 USD
CY2016 acur Inventory Valuation Written Off Finished Goods
InventoryValuationWrittenOffFinishedGoods
-64000 USD
CY2015 acur Inventory Valuation Written Off Finished Goods
InventoryValuationWrittenOffFinishedGoods
0 USD
CY2016 acur Inventory Reserve Expense Finished Goods
InventoryReserveExpenseFinishedGoods
26000 USD
CY2015 acur Inventory Reserve Expense Finished Goods
InventoryReserveExpenseFinishedGoods
70000 USD
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
243000 USD
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
346000 USD
CY2016Q4 us-gaap Inventory Gross
InventoryGross
341000 USD
CY2015Q4 us-gaap Inventory Gross
InventoryGross
346000 USD
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3100000 USD
CY2015Q4 acur Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
400000 USD
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10800000 USD
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
10900000 USD
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
100000 USD
CY2015 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
CY2016Q4 us-gaap Retail Related Inventory
RetailRelatedInventory
260000 USD
CY2016 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
11834000 shares
CY2015 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
10777000 shares
CY2016 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
36000 shares
CY2015 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
19000 shares
CY2016 acur Incremental Common Shares Attributable To Conversion Of Common Stock
IncrementalCommonSharesAttributableToConversionOfCommonStock
11834000 shares
CY2015 acur Incremental Common Shares Attributable To Conversion Of Common Stock
IncrementalCommonSharesAttributableToConversionOfCommonStock
10777000 shares
CY2016 acur Incremental Common Shares Attributable To Restricted Stock
IncrementalCommonSharesAttributableToRestrictedStock
36000 shares
CY2015 acur Incremental Common Shares Attributable To Restricted Stock
IncrementalCommonSharesAttributableToRestrictedStock
19000 shares
CY2016 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2016 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2015 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2015Q4 us-gaap Costs And Expenses
CostsAndExpenses
3389000 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-710000 USD
CY2015Q4 us-gaap Marketable Securities
MarketableSecurities
10837000 USD
CY2016Q4 us-gaap Marketable Securities
MarketableSecurities
0 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
5910000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
14135000 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
417000 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
268000 USD
CY2015Q4 us-gaap Inventory Net
InventoryNet
276000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
309000 USD
CY2015Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
37000 USD
CY2016Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
0 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
867000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1013000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1431000 USD
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1638000 USD
CY2016Q4 us-gaap Assets
Assets
8208000 USD
CY2015Q4 us-gaap Assets
Assets
16961000 USD
CY2016Q4 us-gaap Other Assets
OtherAssets
0 USD
CY2015Q4 us-gaap Other Assets
OtherAssets
175000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
77000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
110000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
703000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
564000 USD
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
27000 USD
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
45000 USD
CY2016Q4 acur Sales Returns Liability Current
SalesReturnsLiabilityCurrent
304000 USD
CY2015Q4 acur Sales Returns Liability Current
SalesReturnsLiabilityCurrent
205000 USD
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2376000 USD
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2320000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
7025000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
9061000 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
118000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
118000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
375763000 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
375157000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-374698000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367310000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-65000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
1183000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
7900000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8208000 USD
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2979000 USD
CY2016 us-gaap Royalty Revenue
RoyaltyRevenue
149000 USD
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
5000 USD
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
423000 USD
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
662000 USD
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6516000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-6557000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16961000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4028000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2608000 USD
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8994000 USD
CY2016 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
60000 USD
CY2015 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
166000 USD
CY2016 us-gaap Interest Expense
InterestExpense
893000 USD
CY2015 us-gaap Interest Expense
InterestExpense
1157000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7388000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4989000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-7388000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-4989000 USD
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
65000 USD
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-52000 USD
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7323000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5041000 USD
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-831000 USD
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-988000 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11870000 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10796000 shares
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11870000 shares
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10796000 shares
CY2016 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
392000 USD
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
11021000 USD
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
12588000 USD
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 USD
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000 USD
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5430000 USD
CY2016 us-gaap Interest Paid
InterestPaid
576000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-107000 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
139000 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4000 USD
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
3500000 USD
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
5250000 USD
CY2016 us-gaap Revenues
Revenues
4464000 USD
CY2015 us-gaap Revenues
Revenues
8587000 USD
CY2016 acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
451000 USD
CY2015 acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
656000 USD
CY2016 us-gaap Inventory Write Down
InventoryWriteDown
26000 USD
CY2015 us-gaap Inventory Write Down
InventoryWriteDown
330000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-4001000 USD
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2015 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
170000 USD
CY2016 acur Milestone Revenue
MilestoneRevenue
0 USD
CY2015 acur Milestone Revenue
MilestoneRevenue
2500000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
5052000 USD
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-52000 USD
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
65000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
606000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
588000 USD
CY2015 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2016 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
18000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
33000 USD
CY2015 acur Issuance Of Common Stock Value Under Market Offerings
IssuanceOfCommonStockValueUnderMarketOfferings
217000 USD
CY2015 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
7033000 USD
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
138000 USD
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
125000 USD
CY2016 acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
26000 USD
CY2015 acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
330000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
588000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
606000 USD
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
145000 USD
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
186000 USD
CY2016 acur Amortization Of Bond Premium In Marketable Securities
AmortizationOfBondPremiumInMarketableSecurities
31000 USD
CY2015 acur Amortization Of Bond Premium In Marketable Securities
AmortizationOfBondPremiumInMarketableSecurities
127000 USD
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
207000 USD
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
207000 USD
CY2016 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-37000 USD
CY2015 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-29000 USD
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
59000 USD
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
302000 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-149000 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-54000 USD
CY2016 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 USD
CY2015 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-218000 USD
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-175000 USD
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
175000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-33000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-353000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5563000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3688000 USD
CY2016 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
172000 USD
CY2015 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
127000 USD
CY2016 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
CY2015 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5291000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2539000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2069000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3079000 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
1729000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2696000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1711000 USD
CY2015 us-gaap Interest Paid
InterestPaid
844000 USD
CY2016 acur Provision For Sales Returns
ProvisionForSalesReturns
99000 USD
CY2015 acur Provision For Sales Returns
ProvisionForSalesReturns
267000 USD
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3522000 USD
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10873000 USD
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3830000 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
75000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
214000 USD
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
14000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
10798000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
108000 USD
CY2016 acur Proceeds From Market Offering Of Shares
ProceedsFromMarketOfferingOfShares
0 USD
CY2015 acur Proceeds From Market Offering Of Shares
ProceedsFromMarketOfferingOfShares
225000 USD
CY2016 us-gaap Repayments Of Debt
RepaymentsOfDebt
2540000 USD
CY2015 us-gaap Repayments Of Debt
RepaymentsOfDebt
1960000 USD
CY2016 acur Proceeds From Registered Direct Offering
ProceedsFromRegisteredDirectOffering
0 USD
CY2015 acur Proceeds From Registered Direct Offering
ProceedsFromRegisteredDirectOffering
7636000 USD
CY2016 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
2000 USD
CY2015 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
3000 USD
CY2016 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000 USD
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-19000 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-19000 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
28000 USD
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2015Q1 us-gaap Revenues
Revenues
5357000 USD
CY2015Q2 us-gaap Revenues
Revenues
341000 USD
CY2015Q3 us-gaap Revenues
Revenues
210000 USD
CY2015Q4 us-gaap Revenues
Revenues
2679000 USD
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
1239000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-2663000 USD
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-2649000 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-916000 USD
CY2016Q1 us-gaap Revenues
Revenues
224000 USD
CY2016Q2 us-gaap Revenues
Revenues
257000 USD
CY2016Q3 us-gaap Revenues
Revenues
218000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3384000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-3288000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-2250000 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Revenues
Revenues
3765000 USD
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
3362000 USD
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
3336000 USD
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
2287000 USD
CY2016Q4 us-gaap Costs And Expenses
CostsAndExpenses
2036000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3138000 USD
CY2015Q4 acur Debt Instrument Issuance Cost
DebtInstrumentIssuanceCost
97000 USD
CY2016 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-1000 USD
CY2016 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"> Reclassifications</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain reclassifications have been made to the prior year&#8217;s amounts to conform to the current year&#8217;s presentation.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.2in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt">Management Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based on such periodic evaluations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
19000 USD
CY2016Q4 acur Debt Instrument Issuance Cost
DebtInstrumentIssuanceCost
47000 USD
CY2014 acur Inventory Reserve Expense Raw And Packagings
InventoryReserveExpenseRawAndPackagings
260000 USD
CY2016Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
2500000 USD
CY2016Q4 acur Cash Cash Equivalent And Marketable Securities
CashCashEquivalentAndMarketableSecurities
2700000 USD
CY2016Q1 acur Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution
ShareBasedCompensationArrangementShareBasedPaymentSharesReservedForFutureDistribution
66000 shares
CY2013Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13000000 USD
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
60000 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.98
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.52
CY2014Q4 acur Cash And Cash Equivalents And Restricted Cash
CashAndCashEquivalentsAndRestrictedCash
774000 USD
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
33000 USD
CY2016Q4 acur Impairment Of Property Plant And Equipment Reserve
ImpairmentOfPropertyPlantAndEquipmentReserve
-82000 USD
CY2015Q4 acur Impairment Of Property Plant And Equipment Reserve
ImpairmentOfPropertyPlantAndEquipmentReserve
0 USD
CY2016 acur Classification Of Deferred Debt Issuance Costs
ClassificationOfDeferredDebtIssuanceCosts
0 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 acur Accrued Cost Sharing Expenses Clinical Studies
AccruedCostSharingExpensesClinicalStudies
95000 USD
CY2013Q4 us-gaap Secured Debt
SecuredDebt
10000000 USD
CY2016Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6000000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2754000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2807000 USD
CY2015 us-gaap Depreciation
Depreciation
100000 USD
CY2016Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
98000 USD
CY2015Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
0 USD
CY2015 acur Inventory Reserve Expense
InventoryReserveExpense
330000 USD
CY2016 acur Inventory Reserve Expense
InventoryReserveExpense
96000 USD
CY2016Q4 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1
NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1
162000 USD
CY2016Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
82000 USD
CY2016 acur Agreement Termination Notice Description
AgreementTerminationNoticeDescription
Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Termination does not affect a partys rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalets supply of Oxaydo for a transition period.
CY2016 acur Classification Of Debt Discount Premium
ClassificationOfDebtDiscountPremium
0 USD
CY2016Q4 acur Working Capital
WorkingCapital
700000 USD
CY2016Q4 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
2500000 USD
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.2in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Concentration of Credit Risk</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Credit Risk</font></i></strong><font style="FONT-SIZE: 10pt">: Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company&#8217;s excess cash is invested in accordance with the investment policy approved by our Board of Directors that seeks a combination of both liquidity and safety of principal using diversification of investments, through investments such as investment grade corporate debt securities with varying maturities. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, and marketable securities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"> Customers:</font></i></strong> <font style="FONT-SIZE: 10pt">We launched our first Impede Technology product, Nexafed&#174;, in the United States in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. Our accounts receivable arise from our sales of our Nexafed product line and represent amounts due from wholesalers in the health care and pharmaceuticals industries and from chain drug stores. The Company has performed a credit evaluation of its customers and may maintain an allowance for potentially uncollectable accounts. We have not experienced any losses on uncollectable accounts in 2016 or 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Sales to certain of our customers during 2016 and 2015 accounting for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% or more of our annual product sales, whether the product shipment was recognized immediately as a sales or as a deferred sale, is presented below. Sales to customers designated with an &#8221; * &#8221;&#160; accounted for less than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of our annual product sales.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Customer</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 4px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 4px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="35%"> <div>Rite Aid Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="5%"> <div>55</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="5%"> <div>54</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Cardinal Health, Inc.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>13</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>McKesson Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Trade accounts receivable from certain of our customers at December 31, 2016 and 2015 accounting for 10% or more of our gross accounts receivable is presented below. Trade accounts receivable from customers designated with an &#8221; ** &#8221; accounted for less than 10% of our gross trade accounts receivable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.2in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 50%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Customer</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 5px; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="35%"> <div>AmerisourceBergen Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="5%"> <div>35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="5%"> <div>**</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>McKesson Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Cardinal Health, Inc.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>**</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>The Kroger Co.</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>**</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="35%"> <div>Rite Aid Corporation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>**</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="5%"> <div>68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2500000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2485000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2681000 USD
CY2016Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
23000 USD
CY2015Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
42000 USD
CY2016Q4 acur Collaboration Revenue Receivable
CollaborationRevenueReceivable
79000 USD
CY2015Q4 acur Collaboration Revenue Receivable
CollaborationRevenueReceivable
36000 USD
CY2016Q4 acur Royalty Receivable
RoyaltyReceivable
50000 USD
CY2015Q4 acur Royalty Receivable
RoyaltyReceivable
5000 USD
CY2016 acur Increase Decrease In Collaboration Revenue Receivable
IncreaseDecreaseInCollaborationRevenueReceivable
43000 USD
CY2015 acur Increase Decrease In Collaboration Revenue Receivable
IncreaseDecreaseInCollaborationRevenueReceivable
36000 USD
CY2016 acur Increase Decrease In Royalty Receivable
IncreaseDecreaseInRoyaltyReceivable
45000 USD
CY2015 acur Increase Decrease In Royalty Receivable
IncreaseDecreaseInRoyaltyReceivable
5000 USD
CY2016Q4 acur Cash And Cash Equivalents And Restricted Cash
CashAndCashEquivalentsAndRestrictedCash
5181000 USD
CY2015Q4 acur Cash And Cash Equivalents And Restricted Cash
CashAndCashEquivalentsAndRestrictedCash
2485000 USD
CY2016Q4 acur Research And Development Arrangement Remaining Amount Others
ResearchAndDevelopmentArrangementRemainingAmountOthers
50000 USD

Files In Submission

Name View Source Status
0001144204-17-018146-index-headers.html Edgar Link pending
0001144204-17-018146-index.html Edgar Link pending
0001144204-17-018146.txt Edgar Link pending
0001144204-17-018146-xbrl.zip Edgar Link pending
acur-20161231.xml Edgar Link completed
acur-20161231.xsd Edgar Link pending
acur-20161231_cal.xml Edgar Link unprocessable
acur-20161231_def.xml Edgar Link unprocessable
acur-20161231_lab.xml Edgar Link unprocessable
acur-20161231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v461049_10k.htm Edgar Link pending
v461049_ex23-1.htm Edgar Link pending
v461049_ex31-1.htm Edgar Link pending
v461049_ex31-2.htm Edgar Link pending
v461049_ex32.htm Edgar Link pending